Webinar reviews the advantages of electronic Clinical Outcome Assessments (eCOAs) for safer, more efficient COPD studies
PHT Corporation Hosts Upcoming Educational Webinar, “Effective Use, Analysis, and Best Practices of eCOA Data for COPD Research”
<0> For PHT CorporationBrenda Nashawaty, 617-688-3253 </0>
will conduct a webinar entitled, on November 13 at 10-11am and 2-3pm ET. is the leading provider of innovative technology systems used to collect for clinical research.
The webinar will be led by Director of PHT Consulting Services Dr. Susan M. Dallabrida and Associate Scientific Advisor Dr. Sarah Tressel Gary. The program is beneficial for all professionals involved in the development of COPD therapies including protocol development, regulatory affairs, health outcomes, clinical operations, medical affairs, eClinical, and data management.
PHT has implemented eCOA Systems for more than 100 respiratory trials, including pivotal phase III trials in COPD.
instruments are used to measure the patient experience for Clinical Outcome Assessments (COAs). Respiratory trials have used eCOAs for submissions since 1998. This webinar will:
1. Review current literature of COAs in respiratory trials2. Evaluate the current use of COAs in COPD and other respiratory indications3. Analyze studies that have compared electronic to paper data collection4. Examine instruments including BCKQ, CCQ, COPD-PS, EQ-5D, HRU, OEQ, St. George Respiratory Questionnaire, and EXACT-PRO
PHT scientists will review operational data analyses showing key metrics for compliance, along with best practices established by collecting eCOA data in more than 650 global trials. Incorporation of these findings may be used to power more efficient COPD studies and eCOA trial design and use. The use of high quality patient-centered outcomes data is an essential component for the informed decision making of multiple stakeholders, including health economics and outcomes research scientists who look to eCOA for comparative effectiveness and relative effectiveness data.
Dr. Dallabrida has more than 20 years of experience as a senior scientist and project director in research and development, clinical trial design and strategy, and product development. She has led cross-functional drug discovery and product development teams and collaborations in a wide range of therapeutic areas including oncology, cardiovascular disease, hemophilia, dermatology, obesity, and vascular disorders. Dr. Dallabrida has significant regulatory experience in the US and internationally for biologics. She has a broad background in scientific presentations and writing with 20 publications, 14 grants, 3 patents, 18 awards, 31 conference presentations, and 25 abstracts to her credit.
Dr. Dallabrida has been a biotechnology and clinical trial consultant and strategic advisor working with Biogen Idec, Rubin Anders Scientific, Zafgen, Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Children’s Hospital of Boston. She holds a BS in Biology and BA in Chemistry from Bloomsburg University and a PhD in Biochemistry and Molecular Biology from Pennsylvania State University. Dr. Dallabrida conducted her post-doctoral training at Harvard Medical School. Following her post-doctoral studies, she had a translational laboratory at Harvard Medical School for 7 years before moving to biotechnology.
Dr. Sarah Tressel Gary has research experience in hemostasis/thrombosis, platelet biology, angiogenesis, atherosclerosis, and cardiovascular disease. She has extensive in vivo and in vitro lab experience and has conducted preclinical studies in support of trials. To date, Dr. Tressel Gary has co-authored 12 publications and received several honors and awards, including an AHA Postdoctoral Fellowship.
Dr. Tressel Gary holds a BS in Biomedical Engineering from Worcester Polytechnic Institute, an MS in Mechanical Engineering and a Doctor of Philosophy in Bioengineering from Georgia Institute of Technology. Dr. Tressel Gary conducted her post-doctoral research in the Hemostasis and Thrombosis Laboratory at Tufts Medical Center in Boston.
The has more than 75+ years of collective experience in electronic patient reported outcomes and clinical outcome assessments. The Team facilitates pharmaceutical researchers and clinicians to implement optimal eCOA/ ePRO trial design strategies to ensure the success of drug development programs. PHT consults on all aspects of collecting COAs with scientific, regulatory, data management and health outcome expertise.
PHT Corporation helps pharmaceutical companies and CROs conduct clinical trial programs with greater confidence, ease and accuracy. Proven PHT electronic Clinical Outcome Assessment (eCOA) Systems collect patient-driven eData via smartphones, tablets and the web. This data, available via online reporting portal, provides sponsors and clinicians with a real time window into how patients feel and function. PHT has helped trial sponsors collect patient-driven eData in 650+ global trials resulting in 16+ regulatory approvals. PHT offers the regulatory, technological, and scientific expertise today’s market demands and patients deserve. Visit for more information on PHT. Follow PHT on , and .